{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin+3", "query": { "intervention": "Rosuvastatin 3" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 75, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin+3&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-11T19:10:48.910Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06533280", "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Part A, C and D: VH3739937 500 mg", "type": "DRUG" }, { "name": "Part A: VH3739937 100 mg", "type": "DRUG" }, { "name": "Part A and C: Placebo", "type": "DRUG" }, { "name": "Part B: Treatment A", "type": "DRUG" }, { "name": "Part B: Treatment B", "type": "DRUG" }, { "name": "Part B: Treatment C", "type": "DRUG" }, { "name": "Part B: Treatment D", "type": "DRUG" }, { "name": "Part B: Treatment E", "type": "DRUG" }, { "name": "Part D: Probe cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2024-08-02", "completion_date": "2024-08-14", "has_results": false, "last_update_posted_date": "2025-04-22", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533280" }, { "nct_id": "NCT06488105", "title": "Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lipid Disorder", "Hypercholesterolemia", "Cardiovascular Diseases", "Atherosclerosis" ], "interventions": [ { "name": "Statin (rosuvastatin 10 or 40 mg daily, depending on risk)", "type": "DRUG" }, { "name": "Healthy Lifestyle Counseling", "type": "BEHAVIORAL" }, { "name": "Outpatient Followup", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 130, "start_date": "2024-08-05", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06488105" }, { "nct_id": "NCT06279234", "title": "A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus (T2DM)", "Obesity" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "PF-06954522", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2024-02-20", "completion_date": "2025-04-11", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 2, "location_summary": "Anaheim, California • South Miami, Florida", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06279234" }, { "nct_id": "NCT03772262", "title": "Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Interaction Drug Food" ], "interventions": [ { "name": "goldenseal", "type": "DIETARY_SUPPLEMENT" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Midazolam oral solution", "type": "DRUG" }, { "name": "Rosuvastatin Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Washington State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2018-04-05", "completion_date": "2019-03-31", "has_results": false, "last_update_posted_date": "2023-04-28", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03772262" }, { "nct_id": "NCT05444556", "title": "A Study of Imlunestrant (LY3484356) in Female Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 113, "start_date": "2022-07-07", "completion_date": "2022-11-02", "has_results": true, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 3, "location_summary": "Cypress, California • South Miami, Florida • San Antonio, Texas", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "South Miami", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05444556" }, { "nct_id": "NCT00300430", "title": "Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemia", "Coronary Heart Disease", "Mixed Dyslipidemia" ], "interventions": [ { "name": "ABT-335 and rosuvastatin calcium", "type": "DRUG" }, { "name": "ABT-335 and atorvastatin calcium", "type": "DRUG" }, { "name": "ABT-335 and simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1911, "start_date": "2006-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2009-07-23", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 1, "location_summary": "North Chicago, Illinois", "locations": [ { "city": "North Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300430" }, { "nct_id": "NCT05657613", "title": "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "CYP450 Cocktail and Transporter Substrates with Pacritinib", "type": "DRUG" }, { "name": "Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib", "type": "DRUG" }, { "name": "Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-01-03", "completion_date": "2023-06-08", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05657613" }, { "nct_id": "NCT06503679", "title": "A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY4100511 (DC-853) Dose 1", "type": "DRUG" }, { "name": "LY4100511 (DC-853) Dose 2", "type": "DRUG" }, { "name": "LY4100511 (DC-853) Dose 3", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2024-07-16", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06503679" }, { "nct_id": "NCT07316608", "title": "A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1", "type": "DRUG" }, { "name": "Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1", "type": "DRUG" }, { "name": "Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2", "type": "DRUG" }, { "name": "Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2", "type": "DRUG" }, { "name": "Laroprovstat Dose X STP", "type": "DRUG" }, { "name": "Rosuvastatin Dose 1 STP", "type": "DRUG" }, { "name": "Rosuvastatin Dose 2 STP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 44, "start_date": "2026-03-16", "completion_date": "2026-06-05", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07316608" }, { "nct_id": "NCT01101568", "title": "A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Simvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "GSK1292263", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 28, "start_date": "2010-04-14", "completion_date": "2010-06-24", "has_results": false, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-11T19:10:48.910Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01101568" } ] }